Kynam Capital Management, LP Merus N.V. Transaction History

Kynam Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $305,762 - $439,868	21,457 New	21,457 $394,000
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $183,655 - $384,257	-13,137 Reduced 11.25%	103,627 $2.35 Million
Q1 2022 May 13, 2022	SELL	$23.58 - $30.91 $127,190 - $166,728	-5,394 Reduced 4.42%	116,764 $3.09 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $2.44 Million - $3.94 Million	122,158 New	122,158 $3.89 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.92B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.